AMNOG: In January 2011, following pressure to reduce annual spending on the German healthcare budget, price controls were introduced in Germany through the AMNOG based pricing system. There is considerable anxiety within the industry as to whether a feasible price will be received in Germany and given the uncertainties, whether effective launch planning is possible.
Here we summarise the resolutions made by AMNOG for 32 products assessed by March this year.
Learn what products fall under:
- Considerable added benefit
- Resolutions with minor additional benefit
- Resolutions with Non-Quantifiable Additional Benefit
- Resolutions for Orphan Drugs
In December, we will be hosting HTA World 2013, an event focussed on evidence based healthcare for pharmaceutical products. For more information, or to book your place go to www.healthnetworkcommunications.com/hta
I hope you enjoy this ebook and more importantly find it informative and thought provoking.